| Blastocystis hominis |
B. hominis has recently been reclassified
as a protozoan, of which there are thought to be four separate serologic
groups. [1] |
This organism is transmitted via the fecal-oral
route or from contaminated food or water.[2] Prevention can be enhanced by
improving personal hygiene and sanitary conditions.
[3] |
The role of B. hominis in terms of colonization
and disease is still considered controversial. When this organism
is present in the absence of any other parasites, enteric organisms
or viruses, it may be considered the etiological agent of disease.[4]
|
Symptoms can include: diarrhea, cramps, nausea,
fever, vomiting and abdominal pain.[5]B.
hominis has been associated with irritable bowel syndrome, infective
arthritis and intestinal obstruction.[6] |
Metronidazole (Flagyl) is considered the most
effective drug (750 mg tid x 10 days).[7] Iodoquinol (Yodoxin) is also
an effective medication (650 mg tid x 20 days).[8] Recommended therapy can also
eliminate G. lamblia, E. histolytica and D. fragilis, all of which
may be concomitant undetected pathogens and part of patient symptamology.[9] [10] |
| Cryptosporidium spp |
Cryptosporidium spp are coccidian
parasites that belong to the Cryptosporidiidae family.
[11]
|
Infection is thought to occur by environmentally
resistant oocysts, zoonotic transmission, nosocomial transmission
and direct person-to-person contact.
[12]
Contamination of public water supply has been associated
with outbreaks.Raw foods such as unpasturized milk and
raw meat can also harbor the organism.
[13]
|
Cryptosporidium is an important agent
of diarrhea in both the immunocompetant and immunocompromised host.
[14]
The organism inhabits the intestinal mucosa causing
diarrhea.
[15]
Infection in the immunocompromised host
may cause life threatening disease and can disseminate from the intestinal
tract.
[16]
Cryptosporidium is considered an
important opportunistic pathogen in patients with AIDS, and detection
is associated with a poor prognosis.
[17]
|
Acute infections can mimic Crohn’s disease
with villus atrophy, enlarged crypts, and infiltration of the lamina
propria by inflammatory cells.
[18]
Clinical symptoms in the immunocompetant host include
nausea, low-grade fever, abdominal cramps, anorexia and up to 5-10
watery bowel movements a day, which may be followed by constipation.
[19]
Immunocompetent hosts can also be asymptomatic.
[20]
Cryptosporidium in the immunocompromised
host may be ongoing and severe. The length and severity depend on
the ability to reverse the immunosuppression. Extra-intestinal infections
can occur with respiratory symptoms, cholecystitis, hepatitis and
pancreatitis
[21]
Chronic cryptosporidiosis in infants is associated
with failure to thrive
[22]
|
Cryptosporidiosis is generally self-limiting
in immunocompetent patients, lasting approximately 2 weeks.
[23]
Currently, there is no totally effective
therapy for cryptosporidiosis. Refer to the Medical Letter and/or
Sanford Guide for therapeutic protocols in the immunocompromised host.
[24]
|
| Dientamoeba fragilis |
D. fragilis has recently been reclassified
as an ameboflagellate (previously ameba) and is closely related to
Histomonas and Trichomonas species
[25]
|
Because this organism does not have a cyst
stage, there is uncertainty of the mode of transmission.
[26]
Fecal oral transmission thus far has not been documented.
[27]
Higher incidences have been reported for mental institutions,
missionaries and Native Americans of Arizona.D. fragilis
is also common in pediatric populations and patients under the age
of 20.
[28]
|
D. fragilis is known to cause non-invasive
diarrheal illness in humans.90% of children are symptomatic,
whereas only 15-20% of adults are.
[29]
|
The most common symptoms associated with D.
fragilis are intermittent diarrhea, fatigue, abdominal pain, fatigue,
nausea, anorexia, malaise and unexplained eosinophilia.
[30]
Diarrhea is predominately seen during the
first 1-2 weeks of infection and abdominal pain may persist for 1-2
months.
[31]
|
Iodoquinol (650 mg tid x 20 days) or
Tetracycline (500 mg qid x 10 days) or Metronidazole (500-750
mg tid x 10 days) have been used to treat D. fragilis.
[32]
Another alternative is Paromomycin
(500 mg tid x 7 days).
[33]
|
| Entamoeba coli |
This organism is a protozoan belonging to
the amebae family.
[34]
|
Entamoeba coli has a worldwide distribution,
the prevalence is generally greater in warmer climates.
[35]
The cyst which is the infectious form is
ingested from contaminated food and water. Direct transmission can
also occur via the fecal-oral-route.
[36]
|
While Entamoeba coli is the most common
ameba isolated in humans, it is considered non-pathogenic.
[37]
|
Entamoeba coli is not associated with
intestinal symptoms. |
The Medical Letter and Sanford Guide provide
no therapeutic recommendations for Entamoeba coli.Treatment
is not recommended for non-pathogenic amebae. Improving sanitary
conditions and personal hygiene help to prevent infection.
[38]
|
| Entamoeba dispar |
E. dispar is a protozoan that belongs
to the amebae family.
[39]
|
Transmission is from the ingestion of infective
cysts in contaminated food or water. Person-to-person contact is
also a source of transmission.
[40]
|
Entameoba dispar is considered to be
non-pathogenic in humans.
[41]
|
This particular species of Entameoba
is not known to produce intestinal symptoms, nor is it invasive in
humans.
[42]
|
The Medical Letter and Sanford Guide provide
no therapeutic recommendations for Entamoeba dispar.Treatment
is generally not recommended for non-pathogenic amebae, however this
recommendation is based upon being able to accurately differentiate
E. dispar from pathogenic E. histolytica.
[43]
|
| Entamoeba hartmanni |
This organism belongs to the amebae family.
[44]
|
Transmission is related to the ingestion of
cysts from contaminated food or water.
[45]
|
Entamoeba hartmanni is not considered
a pathogen in humans. While early research identified this organism
as a potential pathogen, subsequent studies were unable to adequately
confirm.
[46]
|
Entamoeba hartmanni is not routinely
associated with clinical symptoms.
[47]
|
Treatment for E. hartmani is usually
not recommended, accordingly the Medical Letter and the Sanford
guide have no therapeutic recommendations.
[48]
|
| Entamoeba histolytica |
E. histolytica belongs to the ameba
family of protozoa.
[49]
|
This organism has been recovered worldwide,
though is more prevalent in the tropics and subtropics. In
unsanitary conditions, infection rates are equivalent to tropical
regions despite colder climates.
[50]
Humans are the reservoir for E. histolytica
and can transmit the parasite to other humans, primates, cats, dogs
and possibly pigs.
[51]
|
E. histolytica is pathogenic for humans,
causing invasive intestinal and extraintestinal amebiasis.
[52]
In 2-8% of infected individuals, invasion of the intestinal
mucosa occurs with dissemination to other organs (most frequently
the liver).
[53]
The organism is capable of inducing both
humoral and cellular immune responses.
[54]
|
While a large number of people worldwide are
infected with E. histolytica, only a few manifest clinical
symptoms.
[55]
Asymptomatic patients may excrete cysts
for only a short period of time and are essentially unaffected and
never experience symptoms.
[56]
Some patients may experience symptoms that
mimic ulcerative colitis. Others still may have a gradual onset of
symptoms including diarrhea, colicky abdominal pain, and tenesmus.The
incubation time for those symptomatic can vary from 1-4 weeks. With
the onset of dysentery, diarrhea can occur with up to 10 movements
a day that are characterized by blood-tinged mucus.
[57]
|
E. histolytica should be treated even
if patients are asymptomatic.Paromomycin 500 mg
tid x 7 days) or Iodoquinol (650 mg tid x 20 days) Diloxanide
Furoate (500 mg tid x 10 days are used for asymptomatic patients
with cysts in the gut lumen, but are ineffective for extraintestinal
infections.
[58]
Metronidazole (500-750 mg tid x 10
days) or Tinidazole (1g q12h x 3 days), or Ornidazole
500 mg q12h x 5 days) followed by either Paromomycin 500 mg
tid x 10 days) or Iodoquinol (650 mg tid x 20 days)
are used for patients with mild to moderate disease.
[59]
Severe extraintestinal infection requires
IV therapy, refer to the Sanford
guide for therapeutic guidelines.
[60]
|
| Giardia lamblia |
Giardia lamblia is the most
commonly diagnosed flagellate in the intestinal tract.
[61]
Giardia intestinalis and Giardia
duodenalis are also used as names for this organism.
[62]
|
Infection occurs via fecal-oral transmission
or from food and water contaminated with the cysts.
[63]
Giardia lamblia has a worldwide distribution,
though is more common in warmer climates than cooler ones. Isolation
of the organism is more prevalent in children or those living in close
quarters with poor sanitary conditions.
[64]
|
Giardia lamblia is considered a pathogen
in humans.
[65]
|
Most people infected with G. lamblia are
asymptomatic. For those symptomatic, there can be an acute and a chronic
phase of infection.
[66]
After an incubation period of 2-20 days, symptoms of
watery diarrhea, nausea, low grade fever and chills can occur lasting
only a few days.
[67]
Acute infection can mimic food poisoning, bacillary dysentery,
viral enteritis, acute intestinal amebiasis or travelers diarrhea.
One point of differentiation is the lack of blood, mucus and cellular
exudates in the stool with G. lamblia.
[68]
In the chronic phase, symptoms can include recurrent
foul smelling diarrhea, abdominal distention, belching and heartburn.
[69]
Chronic Giardiasis may lead to dehydration, malabsorption
and impaired pancreatic function.
[70]
|
The drug of choice is Metronidazole
(250 mg tid x 5 days) and is recommended also for immunocompetent
hosts with self limiting infections. Treatment helps prevent transmission
of the organism and reduce the duration of symptoms.
[71]
Other therapeutic alternatives include Furazolidone
(100 mg qid x 7-10 days) or Tinidazole (2g once).
[72]
Paromomycin (500 mg
4x/day x 7 days) is the alternative for treating G. lamblia
during pregnancy.
[73]
|
| Helminths |
|
|
|
|
|
| Ascaris lumbricoides |
Ascaris lumbricoides is the largest
and most prevalent of all the human intestinal nematodes.
[74]
|
This organism is more prevalent in warm, moist
climates, though it can survive in temperate regions.
[75]
Infection is acquired through the ingestion
of embryonated eggs in contaminated soil.
[76]
|
This organism is a clearly defined pathogen
in humans with infection rates as high as 45% in Central and South
America.
[77]
The pathogenesis of A. lumbricoides is attributed
to (i) the immune response of the host (ii) the effects of larval
migration (iii) the effects of adult worms (iv) nutritional deficiencies
resultant from the adult worms.
[78]
|
Symptoms relate to the migration of the worm
after hatching in the stomach, penetrating the intestinal wall and
migrating through the liver to the lungs. When in the intestine, patients
are usually asymptomatic, unless the worm burden is high. Migration
can result in intestinal blockage, entry into the bile or pancreatic
duct, or liver or peritoneal cavity. Repeated infections or those
with a large volume of eggs can result in pneumonitis (Loeffler’s
syndrome) during the larval migration phase through the lungs. Symptoms
include cough, dyspnea, wheezing or coarse rales, fever and transient
eosinophilia.
[79]
Infection can be terminated by the spontaneous passage
of the adult worms from the anus, mouth or nares.
[80]
|
Mebendazole (100 bid x 3 days) is considered
the most effective drug and is suitable for both children and adults.
Pyrantel pamoate (11 mg/kg once (maximum
1 gram), repeat after two weeks) or Albendazole (400 mg once)
are alternatives, however these drugs are still considered investigational.
[81]
|
| Enterobius vermicularis(Pinworm) |
E. vermicularis is a nematode, and
is the most prevalent parasitic infection in the world.
[82]
|
Infection is more common in the cooler, temperate
regions, and thought to be related to reduced bathing and changing
of underclothes.
[83]
Infection is more prevalent in children and occurs
more commonly in females.
[84]
|
E. vermicularis is considered a pathogenic
organism.
[85]
|
Those infected may be asymptomatic or experience
pruritus from the migration of the worms from the anus to the perianal
skin where the eggs are deposited.
[86]
Other symptoms found in infected children include insomnia,
nervousness, irritability, nightmares and convulsions.
[87]
|
Treatment is with Pyrantel pamoate
(11 mg/kg once (maximum once), repeat after two weeks) or Mebendazole
(100 mg once, repeat after two weeks), or Albendazole (400
mg once, repeat after two weeks). Therapy should always be based upon
evidence of infection and symptomology.
[88]
|
| Strongyloides stercoralis |
S. stercoralis is classified as a nematode.
[89]
|
The organism is more prevalent in tropics
and subtropics, though can survive colder climates.
[90]
The first stage larvae are contaminated in the soil,
and infection occurs from skin penetration where the organism then
travels to the intestine via the blood, lungs, trachea and upper Gastro-intestinal
tract.
[91]
|
S. stercoralis is considered a pathogen
in humans.
[92]
|
Individuals can be asymptomatic, or exhibit
symptoms in three key areas relative to the life cycle of the parasite
and a heavy infective dose.
[93]
Cutaneous penetration may result in pruritis and erythema
when the larvae are in high numbers. With larval migration through
the lungs, infected hosts may develop a cough, shortness of breath,
wheezing, fever, and pneumonia. When there is intestinal infestation,
symptoms can mimic peptic ulcer and there may be damage to the intestinal
mucosa with villous atrophy and crypt hyperplasia. Radiographic findings
may be akin to Crohn’s disease of the proximal small intestine.
[94]
Reactive arthritis has also been associated with a
heavy Strongyloides infection.
[95]
|
Treatment options for Strongyloides include
Ivermectin (200 ug/kg/day x 1-2 days) or Thiabendazole
(25mg/kg.day bid (maximum of 3g/day).
[96]
|
* Treatment protocols sourced from the Medical Letter (03)
or the Sanford
Guide (03).
[1]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 28.
[2]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 31.
[3]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 31.
[4]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 30.
[5]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 30.
[6]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 30.
[7]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 31.
[8]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 31.
[9]
Garcia LS, Bruckner DA. Taxonomy and classification of human parasites.
In: Murray PR, Baron EJ,
Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology.
7th ed. Washington DC:
ASM Press; 1999; 1330.
[10]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 30.
[11]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 60.
[12]
Ortega YR. Cryptosporidium, cyclospora, and isospora.
In: Murray PR, Baron EJ,
Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology.
7th ed. Washington DC:
ASM Press; 1999; 1411.
[13]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 74,75.
[14]
Ortega YR. Cryptosporidium, cyclospora, and isospora.
In: Murray PR, Baron EJ,
Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology.
7th ed. Washington DC:
ASM Press; 1999; 1411.
[15]
Ortega YR. Cryptosporidium, cyclospora, and isospora.
In: Murray PR, Baron EJ,
Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology.
7th ed. Washington DC:
ASM Press; 1999; 1406.
[16]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 76.
[17]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 60,61.
[18]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 63.
[19]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 63.
[20]
Garcia LS, Bruckner DA. Taxonomy and classification of human parasites.
In: Murray PR, Baron EJ,
Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology.
7th ed. Washington DC:
ASM Press; 1999; 1331.
[21]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 65.
[22]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 63.
[23]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 61,71.
[24]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 60.
[25]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 49.
[26]
Leber AL, Movak SM In: Murray
PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical
Microbiology. 7th ed. Washington
DC: ASM Press; 1999; 1401.
[27]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Santa Monica; 2001;
pg 51.
[28]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Santa Monica; 2001;
pg 49.
[29]
Leber AL, Movak SM In: Murray
PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical
Microbiology. 7th ed. Washington
DC: ASM Press; 1999; 1401.
[30]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Santa Monica; 2001;
pg 50.
[31]
Leber AL, Movak SM In: Murray
PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical
Microbiology. 7th ed. Washington
DC: ASM Press; 1999; 1330.
[32]
Leber AL, Movak SM. Intestinal and urogenital amebae, flagellates,
and ciliates. In: Murray
PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical
Microbiology. 7th ed. Washington
DC: ASM Press; 1999; 1401.
[33]
Sanford JP. The
Sanford Guide
to Antimicrobial Therapy. 30th edition. Gilbert DN, Moellering Jr,
RC, Sande MA, eds. Hyde Park (VT): Antimicrobial
Therapy Inc; 2003.
[34]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 6.
[35]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 22.
[36]
Leber AL, Movak SM. Intestinal and urogenital amebae, flagellates,
and ciliates. In: Murray
PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical
Microbiology. 7th ed. Washington
DC: ASM Press; 1999; 1392.
[37]
Leber AL, Movak SM. Intestinal and urogenital amebae, flagellates,
and ciliates. In: Murray
PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical
Microbiology. 7th ed. Washington
DC: ASM Press; 1999; 1398.
[38]
Leber AL, Movak SM. Intestinal and urogenital amebae, flagellates,
and ciliates. In: Murray
PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical
Microbiology. 7th ed. Washington
DC: ASM Press; 1999; 1399.
[39]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 6.
[40]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 21.
[41]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 7.
[42]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 7.
[43]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 21.
[44]
Garcia LS, Bruckner DA. Taxonomy and classification of human parasites.
In: Murray PR, Baron EJ,
Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology.
7th ed. Washington DC:
ASM Press; 1999; 1330.
[45]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 22.
[46]
Leber AL, Novak SM. Intestinal and urogenital parasites. In: Murray
PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical
Microbiology. 7th ed. Washington
DC: ASM Press; 1999; 1392.
[47]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 22.
[48]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 22.
[49]
Garcia LS, Bruckner DA. Taxonomy and classification of human parasites.
In: Murray PR, Baron EJ,
Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology.
7th ed. Washington DC:
ASM Press; 1999; 1330.
[50]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 6.
[51]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 20.
[52]
Leber AL, Novak SM. Intestinal and urogenital parasites. In: Murray
PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical
Microbiology. 7th ed. Washington
DC: ASM Press; 1999; 1392.
[53]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 9.
[54]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 6.
[55]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 6.
[56]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 9.
[57]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 9.
[58]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 18.
[59]
Sanford JP. The
Sanford Guide
to Antimicrobial Therapy. 30th edition. Gilbert DN, Moellering Jr,
RC, Sande MA, eds. Hyde Park (VT): Antimicrobial
Therapy Inc; 2003.
[60]
Sanford JP. The
Sanford Guide
to Antimicrobial Therapy. 30th edition. Gilbert DN, Moellering Jr,
RC, Sande MA, eds. Hyde Park (VT): Antimicrobial
Therapy Inc; 2003.
[61]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 36.
[62]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 36.
[63]
Leber AL, Novak SM. Intestinal and urogenital parasites. In: Murray
PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical
Microbiology. 7th ed. Washington
DC: ASM Press; 1999; 1399.
[64]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 36.
[65]
Garcia LS, Bruckner DA. Taxonomy and classification of human parasites.
In: Murray PR, Baron EJ,
Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology.
7th ed. Washington DC:
ASM Press; 1999; 1330.
[66]
Leber AL, Novak SM. Intestinal and urogenital parasites. In: Murray
PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical
Microbiology. 7th ed. Washington
DC: ASM Press; 1999; 1399.
[67]
Leber AL, Novak SM. Intestinal and urogenital parasites. In: Murray
PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical
Microbiology. 7th ed. Washington
DC: ASM Press; 1999; 1399.
[68]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 39.
[69]
Leber AL, Novak SM. Intestinal and urogenital parasites. In: Murray
PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical
Microbiology. 7th ed. Washington
DC: ASM Press; 1999; 1399.
[70]
Leber AL, Novak SM. Intestinal and urogenital parasites. In: Murray
PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical
Microbiology. 7th ed. Washington
DC: ASM Press; 1999; 1399.
[71]
Leber AL, Novak SM. Intestinal and urogenital parasites. In: Murray
PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical
Microbiology. 7th ed. Washington
DC: ASM Press; 1999; 1401.
[72]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 46.
[73]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 46.
[74]
Ash LR, Orihel TC. Intestinal Helminths. In: Murray
PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical
Microbiology. 7th ed. Washington
DC: ASM Press; 1999; 1424.
[75]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 266.
[76]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 266.
[77]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 266.
[78]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 269.
[79]
Ash LR, Orihel TC. Intestinal Helminths. In: Murray
PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical
Microbiology. 7th ed. Washington
DC: ASM Press; 1999; 1424.
[80]
Ash LR, Orihel TC. Intestinal Helminths. In: Murray
PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical
Microbiology. 7th ed. Washington
DC: ASM Press; 1999; 1424.
[81]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 272,273.
[82]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 274.
[83]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 274.
[84]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 276.
[85]
Sharp SE. Commensal and Pathogenic microorganisms of humans. In:
Murray PR, Baron EJ, Pfaller
MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology.
7th ed. Washington DC:
ASM Press; 1999; 25.
[86]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 274.
[87]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 276.
[88]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 276.
[89]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 265.
[90]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 286.
[91]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 288.
[92]
Sharp SE. Commensal and Pathogenic microorganisms of humans. In:
Murray PR, Baron EJ, Pfaller
MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology.
7th ed. Washington DC:
ASM Press; 1999; 25.
[93]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 288.
[94]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 288,289.
[95]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 290.
[96]
Garcia, LS. Diagnostic Medical Parasitology. 4 th
ed. Washington DC:
ASM; 2001; 292.
|